Raniji 30ml Injection

Raniji 30ml Injection contains Ranitidine HCl 25mg/ML, a histamine H2 receptor antagonist used to reduce stomach acid production and treat conditions like peptic ulcers and gastroesophageal reflux disease.

Benefits

Ranitidine HCl 25mg/ML Injection offers rapid relief from conditions caused by excess stomach acid, including ulcers, gastroesophageal reflux disease (GERD), and hyperacidity. Administered intravenously or intramuscularly, it provides a quick onset of action, which is crucial in acute situations or when oral medication is not feasible. By blocking histamine H2 receptors, it effectively alleviates symptoms such as heartburn and supports the healing of gastric ulcers.

Uses and Indications

• Short-term treatment of active duodenal and benign gastric ulcers.
• Management of gastroesophageal reflux disease (GERD), including reflux oesophagitis and symptomatic relief.
• Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
• Prophylaxis against gastrointestinal haemorrhage from stress ulceration in seriously ill patients.
• Prevention of recurrent haemorrhage in patients with bleeding peptic ulcers.
• Prophylaxis of acid aspiration before general anaesthesia, particularly in obstetric patients during labour.
• As a short-term alternative for patients unable to take oral ranitidine.

The Raniji 30ml Injection contains:

• Ranitidine Hydrochloride 25mg/ML (active ingredient).
• Excipients: phenol (as preservative), monobasic potassium phosphate, dibasic sodium phosphate (as buffers), hydrochloric acid (to adjust pH), and water for injections.

Dosage and Administration

1. Raniji 30ml Injection is administered via intramuscular (IM) or intravenous (IV) routes.
2. The usual adult dose is 50 mg (2 mL of 25mg/ML solution) every 6 to 8 hours.
3. For slow intravenous injection, dilute 50 mg to a volume of 20 mL and administer over at least 2 minutes.
4. For intermittent intravenous infusion, dilute 50 mg in 5% dextrose or 0.9% sodium chloride injection to a concentration no greater than 0.5 mg/mL (e.g., 100 mL) and infuse over 15 to 20 minutes.
5. Intramuscular injection typically requires no dilution and should be injected into a large muscle mass.
6. Dosage and administration should always be determined by a qualified healthcare professional based on the patient's condition and response.

Storage and Disposal

• Store Raniji 30ml Injection between 2°C and 25°C.
• Protect from light and do not allow it to freeze.
• Keep out of reach of children.
• Discard all solutions of Ranitidine Injection after use.
• Dispose of unused or expired medication according to local regulations; do not dispose in wastewater or household garbage.

Precautions and Safety

• Symptomatic improvement with Ranitidine does not rule out the presence of gastric malignancy.
• Use with caution in patients with kidney or liver impairment; dosage adjustments may be necessary.
• Patients with a history of acute porphyria should avoid this medication.
• Long-term use of H2 receptor antagonists may lead to vitamin B12 deficiency.
• Ranitidine can interact with other medications; inform your doctor or pharmacist about all medicines you are taking.
• Rapid intravenous administration of ranitidine has been rarely associated with bradycardia and AV block.
• The Central Drugs Standard Control Organisation (CDSCO) has advised manufacturers in India to monitor NDMA levels in ranitidine products due to potential health risks.

Side Effects and Risks

• Common side effects include headache, dizziness, diarrhea, and pain, burning, or itching at the injection site.
• Less common but serious side effects can include allergic reactions (severe itching, rash, hives, swelling of face/throat/tongue/lips/eyes/hands/feet/ankles/lower legs), slow heartbeat, difficulty breathing or swallowing, hoarseness, upset stomach, extreme tiredness, unusual bleeding or bruising, lack of energy, loss of appetite, pain in the upper right part of the stomach, yellowing of the skin or eyes (jaundice), and flu-like symptoms.
• Other reported side effects include mental confusion, muscle pain, gynecomastia, inflammation of blood vessels (vasculitis), inflammation of the pancreas (pancreatitis), inflammation of the liver (hepatitis), and inflammation in the kidney (interstitial nephritis).
• There is an increased risk of pneumonia and infectious diarrhoea with H2 receptor antagonists.

Disclaimer

Use this medicine only under the prescription and guidance of a qualified doctor or pharmacist.